Business Focus and Strategy - The company reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales since August 10, 2017[17]. - The company operates in the genetic testing industry, providing both medical products and services based on gene sequencing technology, with a focus on clinical applications and project-based development[38]. - The company plans to focus on the fastest-growing segments of genetics and oncology, aiming for complete control over genetic diseases and extending oncology diagnostics from late-stage to early screening[68]. - The company is focusing on the development of tumor early screening and diagnosis products based on core patented technologies[117]. - The company is expanding its business into oncology, particularly in liquid biopsy and immune gene testing for late-stage tumors[119]. Financial Performance - The company's operating revenue for 2020 was ¥1,540,385,732.47, a decrease of 4.78% compared to 2019[19]. - The net profit attributable to shareholders for 2020 was ¥210,665,188.77, down 46.07% from the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥114,509,221.95, a decline of 61.03% year-over-year[19]. - The basic earnings per share for 2020 was ¥0.60, a decrease of 45.45% compared to ¥1.10 in 2019[19]. - The company achieved a total revenue of approximately CNY 1.47 billion, with a net profit of CNY 204.43 million, reflecting a significant growth in performance[113]. Investments and Assets - The total assets at the end of 2020 were ¥3,243,969,209.24, reflecting a growth of 5.71% from the end of 2019[20]. - The company has increased its stake in Fujian Huirui from 19.412% to 20.956% after acquiring 1.544% equity for RMB 1,034,480[47]. - The company reported a total investment of 53,815,000.00 yuan, with 61.85% in cash and bank deposits[104]. - The company has guaranteed a total of 10,000 million CNY for its subsidiaries, which represents 4.19% of the company's net assets[177]. Research and Development - The company has established strategic partnerships with 10x Genomics and New Gen Yuan to expand its research service offerings, now totaling over 40 types of research service products[51]. - The company has published 339 SCI articles with a cumulative impact factor exceeding 2544, showcasing its strong clinical research capabilities[52]. - R&D investment amounted to ¥129,357,051.73, representing 8.40% of operating revenue[88]. - The number of R&D personnel decreased by 2.94% to 132 in 2020, accounting for 8.73% of total employees[87]. Market Position and Competition - The company has established a strong market position in genetic testing, leveraging its first-mover advantage and continuously innovating products and channels to drive revenue growth[41]. - The company experienced a significant drop in the weighted average return on equity, which fell to 8.64% from 18.35% in 2019[19]. - The company faced risks from intensified market competition and declining service prices in the gene sequencing industry, which could negatively impact future performance if service quality and technology do not improve[126]. Compliance and Governance - The company operates under the supervision of the China Securities Regulatory Commission and adheres to the regulations set forth by the Shenzhen Stock Exchange[10]. - The company has established a strict internal governance system, but the expansion of operations may increase management challenges and risks[125]. - The company has maintained compliance with all regulatory requirements and has not faced any administrative penalties or major civil litigation in the last five years[143]. Shareholder and Equity Information - Major shareholder Gao Yang holds 13.89% of the shares, totaling 49,260,572, with 36,945,429 shares under lock-up conditions[197]. - The company has seen a total of 56,798,839 shares added to the restricted shares during the reporting period[196]. - The company has implemented a share repurchase plan in accordance with the established guidelines, ensuring compliance with regulatory requirements[192]. - The controlling shareholder, Gao Yang, is a recognized expert in the field of genomics and serves as the chairman and CEO of the company[200]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report, indicating potential future challenges[4]. - The company reported a potential risk of declining gross margins due to industry regulation uncertainties and increased market competition, which could significantly affect profit levels[126]. - The company’s ability to manage accounts receivable effectively is crucial to avoid liquidity issues as sales scale expands[127].

Financial Performance - The company's operating revenue for Q1 2021 was ¥334,982,971.78, a decrease of 9.46% compared to ¥369,973,449.87 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was ¥21,242,485.44, down 65.95% from ¥62,393,298.10 in the previous year[7] - Basic earnings per share for Q1 2021 were ¥0.0599, a decline of 66.08% from ¥0.1766 in the previous year[7] - The estimated net profit for the period from the beginning of the year to the next reporting period is projected to be between 40 million and 60 million yuan, representing a decrease of 65.95% compared to the same period last year, which was 117.47 million yuan[24] - Basic earnings per share are expected to decline to between 0.1128 and 0.1692 yuan per share, down 65.95% from 0.3313 yuan per share in the same period last year[24] - Total comprehensive income for the first quarter was CNY 20,948,311.58, compared to CNY 60,048,341.05 in the previous period[45] Cash Flow and Liquidity - The net cash flow from operating activities was -¥106,619,684.26, an improvement of 29.92% compared to -¥152,146,155.23 in the same period last year[7] - Cash and cash equivalents decreased by 34.14% to 414.46 million yuan, primarily due to payments for raw materials and fixed asset purchases[16] - The company received 22.47 million yuan in cash related to operating activities, a 1719.10% increase, mainly from the recovery of performance guarantees[16] - Cash flow from operating activities generated a net outflow of CNY 106,619,684.26, compared to a net outflow of CNY 152,146,155.23 in the previous period[52] - Cash and cash equivalents at the end of the period totaled CNY 414,462,361.65, down from CNY 629,308,298.94 at the beginning of the period[53] - The ending balance of cash and cash equivalents was 1,840,630.30 yuan, down from 4,288,037.44 yuan in the previous period[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,175,283,029.22, a decrease of 2.12% from ¥3,243,969,209.24 at the end of the previous year[7] - The company's total liabilities as of March 31, 2021, were approximately 731.64 million yuan, down from approximately 821.52 million yuan at the end of 2020[36] - Total liabilities decreased to CNY 109,134,746.38 from CNY 148,113,528.38[40] - The equity attributable to shareholders of the parent company was CNY 4,527,857,606.37, down from CNY 4,563,057,644.73[40] - The company's retained earnings stood at 1,052,858,965.48 yuan, contributing to the total equity attributable to shareholders of 2,388,438,682.50 yuan[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,030[10] - The largest shareholder, Gao Yang, held 13.89% of the shares, amounting to 49,260,572 shares, with 36,945,429 shares pledged[10] - The company repurchased a total of 3,907,400 shares, accounting for approximately 1.1018% of the total share capital, with a total transaction amount of 160.39 million yuan[19] Government and Regulatory Matters - The company received government subsidies amounting to ¥422,389.51 during the reporting period[8] - The company has terminated the review of its non-public offering of A-shares by the China Securities Regulatory Commission, which did not significantly impact its financial status[17] - The company has revised its employee stock ownership plan to utilize 3.9 million repurchased shares, aligning with its long-term strategic development[20] Future Outlook and Strategy - The company anticipates a slowdown in the growth rate of medical product and service testing due to a continuous decline in birth rates, leading to a decrease in overall gross profit margin[24] - The company plans to accelerate product iteration and upgrade to improve the proportion of high-margin products and services, aiming to enhance overall gross profit margin levels[24] - Recent central bank statements on fertility issues are expected to stimulate market demand for prenatal testing products, which the company aims to leverage through its first-mover and technological advantages[24] Research and Development - Research and development expenses for Q1 2021 were CNY 31,015,909.78, compared to CNY 29,580,787.68 in the previous year[43] - The company reported an investment loss of CNY 10,069,473.09, an improvement from a loss of CNY 13,836,212.07 in the previous period[43] Miscellaneous - The first quarter report for 2021 was not audited, indicating potential limitations in financial assurance[67] - The company has not disclosed any new product developments or market expansion strategies in the current report[68] - There were no adjustments made for the new leasing standards in the financial statements[66]

Financial Performance - Operating revenue for the reporting period was ¥367,249,676.64, a decrease of 12.78% year-on-year[7]. - Net profit attributable to shareholders was ¥33,360,093.21, down 47.68% compared to the same period last year[7]. - The company reported a net profit of ¥150,831,923.37 for the year-to-date, a decrease of 51.87% compared to the same period last year[7]. - Basic earnings per share were ¥0.0941, a decrease of 47.66% year-on-year[7]. - The company reported a net profit margin decline, with undistributed profits at CNY 1,017,491,330.25 compared to CNY 866,659,406.87 in the previous period[35]. - The net profit for the third quarter of 2020 was CNY 146,827,353.17, a decrease of 52.7% compared to CNY 310,545,632.88 in the same period last year[49]. - The total profit for the third quarter was CNY 185,096,532.36, down from CNY 360,700,576.93, reflecting a decline of 48.7% year-over-year[49]. - The company reported a comprehensive income total of CNY 32,339,024.42 for the quarter, reflecting a decrease of 48.54% compared to CNY 62,899,802.09 in the previous year[43]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,221,700,435.41, an increase of 4.98% compared to the end of the previous year[7]. - Current liabilities rose to CNY 551,915,642.36, up from CNY 449,718,880.72, indicating an increase of approximately 23%[34]. - Non-current liabilities increased to CNY 329,687,437.50 from CNY 272,111,362.93, marking a rise of around 21%[34]. - Total liabilities reached CNY 721,830,243.65, with current liabilities at CNY 449,718,880.72 and non-current liabilities at CNY 272,111,362.93[65]. - Owner's equity totaled CNY 2,347,046,643.19, including share capital of CNY 354,605,865.00 and retained earnings of CNY 866,659,406.87[65]. Cash Flow - The net cash flow from operating activities was ¥76,004,633.30, an increase of 36.52% compared to the previous year[7]. - The net cash flow from operating activities was -34,706,084.02 CNY, a decrease from 87,352,689.69 CNY in the previous period[56]. - Total cash inflow from operating activities was 987,780,042.70 CNY, compared to 1,106,323,154.00 CNY in the same period last year, indicating a decline of approximately 10.7%[56]. - Cash outflow from operating activities totaled 1,022,486,126.72 CNY, slightly increased from 1,018,970,464.31 CNY[56]. - The net cash flow from investing activities was -69,788,961.38 CNY, compared to -320,555,611.94 CNY in the previous period, showing an improvement[57]. - Cash inflow from financing activities was 380,845,754.88 CNY, up from 176,760,105.60 CNY in the previous period, representing a significant increase of approximately 115.5%[57]. Shareholder Information - The total number of shareholders at the end of the reporting period was 18,739[11]. - The largest shareholder, Gao Yang, holds 13.89% of the shares, amounting to 49,260,572 shares, with a portion pledged[11]. Investments and Expenses - Research and development expenses increased to CNY 33,230,928.07, up 14.83% from CNY 29,009,576.30 year-over-year[41]. - Financial expenses increased by 8054.65% to RMB 9,442,539.82, primarily due to increased loan interest expenses[15]. - The company has ongoing investments in fixed assets totaling CNY 506,778,116.04, down from CNY 541,996,643.13, reflecting a decrease of approximately 6%[33]. - The company recorded a net loss from joint ventures and associates of CNY 28,239,541.49, worsening from a loss of CNY 42,374,451.19 in the previous year[49]. Other Key Information - Non-recurring gains and losses totaled ¥34,693,319.08, primarily from the disposal of non-current assets and government subsidies[8]. - The company plans to implement an employee stock ownership plan with a capital scale not exceeding RMB 39 million, involving the repurchase of 3,900,000 shares[17]. - The company expects to engage in related transactions with Fujian He Rui for tumor-related products and services, estimating a total transaction amount of RMB 10 million[17]. - The company has no overdue commitments from major shareholders or related parties during the reporting period, indicating stable governance[20]. - The third quarter report has not been audited[71].

Financial Performance - The company's operating revenue for the first half of 2020 was approximately ¥720.52 million, a decrease of 4.34% compared to ¥753.24 million in the same period last year[18]. - The net profit attributable to shareholders of the listed company was approximately ¥117.47 million, down 53.17% from ¥250.83 million in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥90.55 million, a decrease of 41.56% compared to ¥154.95 million in the same period last year[18]. - The net cash flow from operating activities was negative at approximately -¥110.71 million, a decline of 449.46% compared to ¥31.68 million in the previous year[18]. - The basic earnings per share were ¥0.3341, down 52.76% from ¥0.7073 in the same period last year[18]. - The total comprehensive income for the first half of 2020 was -7,958,218.97 CNY, compared to -34,162,152.24 CNY in the same period of 2019, showing an improvement[188]. - The company reported a net loss of 2,658.72 million in the current period, indicating a challenging financial environment[200]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.41 billion, an increase of 11.14% from ¥3.07 billion at the end of the previous year[18]. - The company's net assets attributable to shareholders decreased by 1.20% to CNY 2,300,505,168.96 as of the end of the reporting period[60]. - Total liabilities increased to CNY 1,094,510,904.33, up 51.7% from CNY 721,830,243.65[175]. - The total assets of the company reached 14,073.54 million, showing a stable asset base despite the losses[200]. Research and Development - Research and development expenses rose by 5.09% to ¥56.16 million, compared to ¥53.44 million in the previous year[66]. - The company has developed core technologies including PCR-free technology and cSMART liquid biopsy technology, which are widely applied in various fields of genetic testing[49]. - The company is focusing on market expansion and new product development strategies to enhance growth prospects[177]. - Research and development efforts are focused on new product innovations to capture market share[199]. Market and Product Development - The main business focuses on high-throughput sequencing technology for genetic testing and sales of related equipment and reagents[26]. - The company aims to enhance clinical and research services by establishing high-quality local databases for clients[26]. - The company launched the "Liver Screening" product, which can detect early-stage liver cancer 6-12 months in advance, significantly improving treatment opportunities for patients[31]. - The company is actively expanding its business into tumor early screening and gene big data analysis, continuously enriching its product line[59]. - The company aims to expand its early screening capabilities to other cancer types based on the success of the liver cancer screening product[31]. Strategic Partnerships and Collaborations - The company has established partnerships with over 80% of research institutions and universities in China, supporting over 10,000 research projects and providing more than 200,000 research samples[45]. - The company has established strategic partnerships with 10x Genomics and NewGen, enhancing its platform resources and contributing to over 100 publications in high-impact journals[50]. - The company’s reagents are developed in collaboration with Illumina, ensuring high performance and accuracy in sequencing applications[34]. Risks and Challenges - The company faces risks from potential changes in national medical reform policies that could impact the healthcare market[95]. - Increased market competition and declining service prices in the gene sequencing industry pose risks to the company's future performance[96]. - The company must accelerate its research and development efforts to avoid risks associated with technological and product innovation lagging behind market demands[97]. - The company is exposed to foreign business risks, including potential legal and regulatory changes in overseas markets that could adversely affect operations[102]. Shareholder and Equity Information - The company has not distributed cash dividends or bonus shares for the half-year period, indicating a focus on reinvestment[112]. - The total number of shares remains at 354,605,865, with no new shares issued or other changes affecting the total[147]. - The company has a significant number of restricted shares, with a total of 212,889,076 shares at the end of the reporting period[153]. - The company’s stock repurchase is expected to positively impact financial indicators such as basic earnings per share and diluted earnings per share[149]. Operational Performance - The company has maintained a strong operational performance without reliance on significant sales returns, showcasing resilience in its business model[121]. - The company reported a significant increase in financial expenses by 513.17% due to increased long-term borrowings and exchange rate losses[66]. - The company is transitioning its service model towards product sales, enhancing customer stickiness and driving revenue growth[41].

Financial Performance - Revenue for Q1 2020 was CNY 369,973,449.87, an increase of 11.14% compared to CNY 332,884,487.18 in the same period last year[7] - Net profit attributable to shareholders decreased by 62.79% to CNY 62,393,298.10 from CNY 167,685,430.87 year-on-year[7] - Basic and diluted earnings per share fell by 62.66% to CNY 0.1766 from CNY 0.4729 in the same period last year[7] - Net profit for Q1 2020 was CNY 60,048,341.05, a decrease from CNY 166,625,153.50 in the same period last year, reflecting a decline of about 64.0%[46] - The total equity attributable to shareholders of the parent company decreased to CNY 4,522,800,320.79 from CNY 4,692,226,477.59, a decline of approximately 3.6%[42] - The total comprehensive income for the period was -19,335,814.51 yuan, compared to -15,321,701.31 yuan in the previous period, indicating a decline of approximately 26.3%[51] - The net profit for the period was -19,335,814.51 yuan, which is a loss compared to -15,321,701.31 yuan in the previous period, reflecting an increase in losses of about 26.3%[50] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 152,146,155.23, a decline of 810.62% compared to negative CNY 16,708,011.17 in the previous year[7] - Cash and cash equivalents decreased by 24.66% to ¥310,009,184.51 from ¥411,490,040.83, primarily due to payments for raw material purchases and additional investments in a subsidiary[15] - The company reported cash inflows from operating activities totaling 280,599,799.64 yuan, down from 317,652,975.81 yuan in the previous period, a decrease of about 11.6%[53] - The company received $25,019,460.06 in cash related to operating activities, a notable increase from $15,419.73 in the previous period[57] - The ending balance of cash and cash equivalents was $4,288,037.44, compared to $7,558,088.52 in the previous period[58] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,040,861,492.18, a decrease of 0.91% from CNY 3,068,876,886.84 at the end of the previous year[7] - The total liabilities of the company increased from 721,830,243.65 yuan to 782,835,318.00 yuan, reflecting a rise of about 8.5%[38] - The company's non-current assets totaled 1,199,045,718.66 yuan, down from 1,216,282,931.60 yuan[37] - Cash and cash equivalents at the end of the period were 310,009,184.25 yuan, down from 341,925,439.80 yuan at the beginning of the period, a decrease of approximately 9.3%[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,455[11] - The largest shareholder, Gao Yang, holds 13.89% of the shares, amounting to 49,260,572 shares, with 36,450,000 shares pledged[11] - The major shareholder reduced its stake by 7,853,400 shares, representing approximately 2.21% of the total share capital[18] Research and Development - R&D expenses increased by 78.56% to ¥29,580,787.68 from ¥16,565,890.45, mainly due to increased investment in COVID-19 testing and third-generation sequencing reagent development[15] - Research and development expenses for Q1 2020 were CNY 29,580,787.68, significantly higher than CNY 16,565,890.45 in the previous period, indicating an increase of about 78.7%[45] Investment Activities - Investment income plummeted by 116.20% to -¥13,836,212.07 from ¥85,411,865.40, primarily due to the previous year's recognition of investment income from relinquishing control of a subsidiary[15] - The company reported a total of CNY 1,342,365.64 in other income for Q1 2020, with investment losses amounting to CNY 13,836,212.07[45] - Investment losses amounted to -13,862,799.99 yuan, compared to -9,735,687.19 yuan in the previous period, reflecting an increase in losses of approximately 42.5%[49] Corporate Actions - The company did not engage in any repurchase transactions during the reporting period[12] - The company has repurchased a total of 3,907,400 shares, accounting for approximately 1.1018% of the total share capital, with a total transaction amount of 160,386,379.29 yuan[22] - The company plans to implement an employee stock ownership plan using 3.9 million shares that have been repurchased, aligning with its long-term strategic development[23] - The company provided a guarantee for its wholly-owned subsidiary, Beijing Berry, for a credit line of up to ¥100 million to support its business operations[20] - The company acquired an additional 1.544% stake in Fujian HeRui Gene Technology Co., Ltd., increasing its total ownership to 20.956%[19] Management and Governance - The company did not undergo an audit for the first quarter report[60] - The company did not apply new revenue and leasing standards for the current reporting period[59]

Business Focus and Strategy - The company reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales since August 10, 2017[16]. - The company focuses on high-throughput sequencing technology for genetic testing and sales of related equipment and reagents, covering areas such as reproductive health, genetic disease detection, and tumor early diagnosis and screening[28]. - The company is actively pursuing new product development and market expansion strategies to enhance its competitive edge[100]. - The company plans to focus on the rapid development of genetics and oncology markets, aiming for complete control over genetic diseases and early screening for oncological diseases[65]. - The company is actively expanding into consumer-level genetic testing services through its investment in "Yuan Gene," which utilizes WES technology for comprehensive health guidance[61]. Financial Performance - The company's operating revenue for 2019 was ¥1,617,641,301.40, representing a 12.35% increase compared to ¥1,439,789,044.56 in 2018[18]. - The net profit attributable to shareholders for 2019 was ¥390,618,298.15, a significant increase of 45.70% from ¥268,091,948.88 in 2018[18]. - The total assets at the end of 2019 were ¥3,068,876,886.84, a 40.90% increase from ¥2,177,996,626.15 at the end of 2018[19]. - The net assets attributable to shareholders increased by 22.33% to ¥2,328,392,943.97 at the end of 2019, compared to ¥1,903,439,521.30 at the end of 2018[19]. - The total operating revenue for the period was ¥1,617,641,301.40, reflecting a 12.35% year-on-year growth, with basic research services revenue increasing by 174.54% to ¥360,856,518.50[60]. Research and Development - Research and development (R&D) expenses amounted to CNY 124.08 million, a 32.87% increase compared to CNY 93.38 million in 2018, accounting for 7.67% of total revenue[85]. - The company has initiated several R&D projects, including high-throughput sequencing technology for genetic disease detection, which is expected to enhance its market share in precision medicine[84]. - The company is focusing on research and development of tumor early diagnosis and treatment products based on its core patented technology, targeting liquid biopsy and hereditary tumor detection[114]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report, indicating potential future challenges[4]. - The company faces risks related to technological innovation lagging behind industry trends, which could impact its competitive position[118]. - Increased market competition and declining service prices pose a risk to the company's profitability if it cannot leverage its core competitive advantages[118]. - The company relies on foreign suppliers for key raw materials, exposing it to risks from supply shortages and price volatility[118]. Corporate Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and senior management[3]. - The company operates under the supervision of the China Securities Regulatory Commission and is listed on the Shenzhen Stock Exchange[13]. - The company is committed to transparency and accountability in its financial reporting and operational practices[137]. - The company has not faced any administrative or criminal penalties related to the securities market in the last five years[141]. Shareholder Dynamics - The largest shareholder, Gao Yang, holds 13.89% of the shares, totaling 49,260,572 shares, with 36,450,000 shares pledged[200]. - The total number of ordinary shareholders at the end of the reporting period is 21,980, an increase from 20,686 at the end of the previous month[200]. - The report highlights the importance of monitoring shareholder dynamics and potential impacts on corporate governance[200]. Investment and Capital Management - The company plans to invest CNY 400 million to CNY 600 million in the Fujian Big Data Center Industrial Park project in the future[126]. - The company has engaged in entrusted wealth management with a total amount of 5,000,000 RMB during the reporting period, with no overdue amounts[178]. - The company has no significant ongoing construction projects or related investment activities disclosed in the report[173]. Product and Service Offerings - The company offers non-invasive prenatal testing (NIPT) services, including "Bebian" for detecting chromosomal aneuploidies and "Bebian Plus" for additional chromosomal abnormalities, with a focus on 17 types of fetal chromosomal aneuploidies[28]. - The company provides comprehensive genetic testing services for tumors, including non-small cell lung cancer mutation detection and hereditary cancer gene testing, utilizing advanced techniques like cSMART for non-invasive testing[30]. - The company’s whole exome sequencing (WES) can analyze approximately 20,000 target genes, aiding in the diagnosis of over 7,000 single-gene hereditary diseases[29]. Market Position and Competitive Advantage - The company has a leading position in the genetic testing industry, particularly in reproductive health and oncology, leveraging its proprietary technologies and strategic partnerships[43]. - The company has established partnerships with over 80% of research institutions, universities, and tertiary hospitals in China, expanding its business into overseas markets[45]. - The company is committed to transforming sequencing technology into clinical applications, providing laboratory solutions tailored to customer needs[28].

Financial Performance - Net profit attributable to shareholders decreased by 31.52% to CNY 63,757,873.58 for the reporting period[7] - Operating revenue for the reporting period was CNY 421,042,161.43, reflecting a growth of 9.72% year-on-year[7] - Basic earnings per share decreased by 30.74% to CNY 0.1798 for the reporting period[7] - The weighted average return on equity was 3.12%, down by 2.20% compared to the previous year[7] - The company announced a cumulative net profit forecast of 410 million yuan for the year, representing a 52.93% increase compared to the previous year[24] - Basic earnings per share are expected to be 1.1562 yuan, reflecting a growth of 52.93% compared to the previous year[24] - Net profit for Q3 2019 was CNY 62,899,802.09, a decrease of 31.5% from CNY 92,052,574.39 in Q3 2018[45] - The total comprehensive income for Q3 2019 was CNY 62,899,802.09, down from CNY 92,783,760.16 in Q3 2018[46] - The total comprehensive income for the third quarter was CNY 310.55 million, compared to CNY 240.57 million in the same period last year, marking an increase of 29.1%[54] Assets and Liabilities - Total assets increased by 25.55% to CNY 2,734,369,531.68 compared to the end of the previous year[7] - Current assets totaled CNY 1,726,846,807.10, up from CNY 1,357,202,348.22, indicating a growth of about 27.3% year-over-year[35] - Total liabilities reached CNY 530,181,948.30, up from CNY 235,675,610.33, which is an increase of approximately 125.5%[36] - The company's equity attributable to shareholders increased to CNY 2,189,980,285.23 from CNY 1,903,439,521.30, representing a growth of about 15.1%[37] - The total liabilities as of Q3 2019 amounted to CNY 2,438,510.35, compared to CNY 2,166,995.98 in the previous year[42] - Total current liabilities were CNY 225,379,928.00, with accounts payable at CNY 82,835,403.56 and accrued employee compensation at CNY 48,100,584.38[70] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 87,352,689.69, an increase of 2.44%[7] - Cash inflow from operating activities totaled 1,106,323,154.00 CNY, up from 1,041,980,100.07 CNY in the previous year, reflecting a growth of approximately 6.5%[61] - Cash outflow from operating activities was 1,018,970,464.31 CNY, compared to 956,704,120.22 CNY last year, resulting in a net cash flow from operating activities of 87,352,689.69 CNY, slightly up from 85,275,979.85 CNY[61] - Investment activities resulted in a net cash outflow of -320,555,611.94 CNY, worsening from -89,965,595.37 CNY in the previous year[62] - Financing activities generated a net cash inflow of 169,030,195.07 CNY, compared to 6,284,598.12 CNY last year, showing a substantial increase[62] Shareholder Information - The total number of shareholders at the end of the reporting period was 21,153[10] - The top ten shareholders held a combined 62.94% of the shares, with Tianjin Junruiqi holding 14.03%[10] - Shareholders plan to reduce their holdings, with one shareholder intending to sell up to 19,500,000 shares, approximately 5.4991% of total shares[18] - Tianjin Junruiqi and Mr. Wang Dong's share reduction is consistent with previous intentions and commitments, and does not violate any regulations[19] - During the reporting period, Mr. Zhou Daixing, the company's general manager, increased his shareholding by 447,200 shares, accounting for 0.1261% of the total share capital, with a total investment of 16,414,056 yuan[19] Research and Development - R&D expenses increased by 47.25% to ¥82,263,670.70, reflecting ongoing investment in research and development[16] - The company plans to increase R&D investment in tumor-related products and services, particularly in early screening and diagnosis, to drive revenue growth[24] - Research and development expenses for Q3 2019 were CNY 29,009,576.30, an increase from CNY 26,845,271.05 in Q3 2018[44] - Research and development expenses reached CNY 82.26 million, which is an increase of 47.3% from CNY 55.87 million in the same period last year[52] Investment Activities - The company reported an investment income of ¥49,768,193.09, a significant increase of 4212.02% compared to the previous period[16] - The company reported an investment loss of CNY 21,079,078.33 in Q3 2019, compared to a gain of CNY 5,557,458.80 in the same period last year[45] - The company invested 272,104,829.49 CNY in fixed assets, a substantial increase from 90,109,696.20 CNY in the previous year[62] Other Financial Information - The company did not engage in any repurchase transactions during the reporting period[11] - The company has no securities investments during the reporting period[25] - There are no violations of external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[29] - The company adjusted its financial reporting to reflect new financial instrument standards, impacting the classification of certain investments[72] - The company adopted new financial instrument standards starting January 1, 2019, affecting the classification of certain investments[75] - The third quarter report was not audited[76]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 753,237,670.26, representing a 16.87% increase compared to CNY 644,500,047.78 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached CNY 250,826,232.01, a significant increase of 71.95% from CNY 145,868,860.42 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 154,950,196.88, which is a 9.35% increase compared to CNY 141,702,100.88 in the same period last year[19]. - The basic earnings per share increased to CNY 0.7073, up 71.95% from CNY 0.4114 in the previous year[19]. - The total assets of the company at the end of the reporting period were CNY 2,615,709,027.46, reflecting a 20.10% increase from CNY 2,177,996,626.15 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased to CNY 2,172,781,253.52, a rise of 14.15% from CNY 1,903,439,521.30 at the end of the previous year[19]. - The net cash flow from operating activities was CNY 31,680,890.44, showing a decrease of 71.74% compared to CNY 112,121,144.41 in the same period last year[19]. - The weighted average return on net assets was 12.31%, slightly up from 11.67% in the previous year[19]. Business Operations - The company’s main business includes high-throughput sequencing technology-based genetic testing services and sales of related equipment and reagents[27]. - The genetic testing services are divided into medical products and services, including hereditary and oncology applications[27]. - The oncology application includes non-small cell lung cancer mutation testing and early screening for liver cancer, with significant advancements in early diagnosis projects[28]. - The company is focusing on developing new diagnostic kits and POCT early diagnostic devices for liver diseases[29]. - The company has established a classification model for early diagnosis and screening of liver cancer, marking a significant step forward in research[28]. - The company has expanded the application range of its sequencing instruments to include diverse gene testing projects, enhancing market competitiveness in oncology[32]. - The company has established a strong foundation in basic research services with platforms like Illumina NovaSeq6000 and PacBio Sequel, enhancing its competitive edge in scientific research[33]. - The company has a dual business model, providing both sequencing services and selling sequencing instruments and reagents to medical institutions, which diversifies its revenue streams[34]. Research and Development - Research and development expenses rose to CNY 53,438,610.51, a 71.94% increase due to ongoing investments in genetic testing projects[61]. - The company aims to focus on the rapidly growing fields of genetics and oncology, with a goal of early screening for genetic diseases and cancers[59]. - The company plans to enhance its research and development capabilities to drive innovation in genetic testing technologies[169]. - The company has initiated new product development projects, focusing on genetic technology advancements[169]. Strategic Initiatives - The company invested in "Yuan Gene," a consumer-grade genetic testing service, marking a strategic move into the consumer genetic testing market[55]. - The company has introduced new strategic investors in its subsidiary, reducing its control over the subsidiary but potentially enhancing its financial position[38]. - The company has strategically introduced new investors to Shanmi Holdings to avoid potential negative impacts on its tumor gene detection business[78]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[169]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[5]. - The company has maintained a stable growth in market share, benefiting from early market entry and brand competitiveness, which has driven performance growth[37]. - The company has a professional team with 80% of employees holding advanced degrees, ensuring a stable and skilled workforce[45]. Compliance and Governance - The company has not faced any significant civil lawsuits or arbitrations related to economic disputes[87]. - The company has not engaged in any activities that would violate the regulations regarding the acquisition of listed companies[87]. - The company has ensured that its business operations remain independent from any controlled enterprises[89]. - The company has committed to maintaining independence in its operations, assets, personnel, and finances post-restructuring[89]. Market Position - The company has provided NIPT services to over 3 million pregnant women, covering more than 5,000 diseases and detecting over 10,000 positive cases[47]. - The NIPTplus technology has expanded the range of detectable diseases from 3 to 100, enhancing the accuracy of prenatal testing[41]. - The NextSeq CN500 gene sequencer has received approval to expand its application beyond NIPT to various clinical genetic testing fields, meeting significant market demand[43]. - The company has established a comprehensive product and service system covering genetics and oncology, supported by 13 domestic and international patents and 34 software copyrights[42]. Financial Health - The total liabilities amounted to CNY 428,854,764.41, compared to CNY 235,675,610.33, showing a significant increase of approximately 82%[142]. - The company's equity attributable to shareholders increased to CNY 2,172,781,253.52 from CNY 1,903,439,521.30, representing a growth of around 14.2%[142]. - The company reported a cash balance of CNY 324,802,299.35, down from CNY 423,619,381.62, a decrease of about 23.4%[139]. - The total current liabilities increased to CNY 273,995,949.46 from CNY 225,379,928.00, reflecting a growth of approximately 21.5%[141]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,096[123]. - The largest shareholder, Tianjin Junruiqi Equity Investment, holds 14.55% of shares, totaling 51,605,030 shares[123]. - The second-largest shareholder, Gao Yang, holds 13.89% of shares, totaling 49,260,572 shares, with 30,230,000 shares pledged[123]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[126].

Financial Performance - The company's revenue for Q1 2019 was ¥332,884,487.18, representing a 12.01% increase compared to ¥297,185,149.31 in the same period last year[7]. - Net profit attributable to shareholders was ¥167,685,430.87, a significant increase of 155.36% from ¥65,667,179.26 year-on-year[7]. - The basic earnings per share rose to ¥0.4729, up 155.35% from ¥0.1852 in the previous year[7]. - Net profit for Q1 2019 reached CNY 166,625,153.50, a significant increase of 152.3% from CNY 65,969,830.36 in Q1 2018[44]. - The company expects a net profit attributable to shareholders of approximately CNY 235 million for the first half of 2019, representing a significant increase of 61.10% compared to the same period last year[24]. - Basic earnings per share are projected to grow to CNY 0.6627, reflecting an increase of 61.10% year-on-year[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,516,911,140.42, reflecting a 15.56% increase from ¥2,177,996,626.15 at the end of the previous year[7]. - The company’s total assets reached CNY 2,516,911,140.42 as of March 31, 2019, up from CNY 2,177,996,626.15 at the end of 2018[34]. - The company’s total liabilities increased to CNY 392,483,348.34 from CNY 235,675,610.33, indicating a rise in financial obligations[35]. - The total liabilities of the company stood at 235,675,610.33 CNY, with total assets amounting to 2,177,996,626.15 CNY, resulting in a debt-to-asset ratio of approximately 10.8%[60]. - Total current assets amounted to ¥185,380,375.57 as of December 31, 2018[62]. - Total non-current assets were ¥4,548,358,596.62, leading to total assets of ¥4,733,738,972.19[62]. Cash Flow - The net cash flow from operating activities was negative at -¥16,708,011.17, a decline of 141.61% compared to ¥40,157,828.41 in the same period last year[7]. - Cash received from tax refunds increased by 1656.05% to ¥1,896,862.91 due to a rise in tax refunds received[16]. - The net cash flow from operating activities was -26,772,013.33 CNY, compared to -3,520,963.28 CNY in the previous period, indicating a significant decline in operational cash generation[54]. - The company reported a significant investment income of CNY 85,411,865.40 in Q1 2019, compared to a loss of CNY 373,081.83 in the same period last year[44]. - The cash outflow from investment activities totaled 206,133,603.73 CNY, compared to 35,211,235.04 CNY in the previous period, showing a substantial increase in investment expenditures[53]. Shareholder Information - The number of shareholders at the end of the reporting period was 14,747[11]. - The top shareholder, Tianjin Junruiqi Equity Investment Partnership, held 14.55% of the shares, amounting to 51,605,030 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Investments and Expenditures - Long-term equity investments grew by 167.37% to ¥207,631,750.70 as a result of new investments in joint ventures[15]. - Cash paid for fixed assets and other long-term assets rose by 462.77% to ¥164,390,843.24 due to increased investment in gene testing equipment[16]. - The company invested 13,000,000.00 CNY in fixed assets and other long-term assets, an increase from 10,000,224.00 CNY in the previous period, representing a 30% rise in investment activities[56]. Operational Challenges - Management expenses decreased by 32.61% to ¥23,416,960.60 as R&D costs were separately listed[16]. - The company reported a significant increase in management expenses compared to the previous period, indicating potential operational challenges[47]. - The company experienced a foreign exchange loss of 969,780.15 CNY during the period, which impacted the overall cash position[53]. Accounting and Reporting - The company adjusted its financial reporting to comply with new accounting standards effective January 1, 2019, impacting the classification of financial assets[64]. - The company did not perform retrospective adjustments for prior period comparative data under the new financial instrument standards[65]. - The first quarter report for 2019 was not audited[65].

Business Transformation - The company reported a significant transformation in its main business from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales since August 10, 2017[16]. - The company’s major shareholder changed from Chengdu Tianxing Instrument (Group) Co., Ltd. to Mr. Gao Yang following a major asset restructuring completed on August 10, 2017[16]. - The company’s main business has not formed a dependency on related party transactions, and these transactions followed fair and reasonable principles[144]. - The completion of significant asset restructuring did not alter the company's main business or actual controller[200]. Financial Performance - The company plans not to distribute cash dividends or issue bonus shares for the year[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and senior management[3]. - The company’s total revenue for the reporting period was approximately ¥1.44 billion, representing a year-on-year growth of 22.93%[59]. - The net profit attributable to shareholders for the reporting period was approximately ¥268 million, reflecting a year-on-year increase of 15.18%[59]. - The company reported a net profit attributable to ordinary shareholders of 268,091,948.88 CNY for 2018, which represents a significant increase compared to 232,749,588.92 CNY in 2017[118]. - The actual distributable profit at the end of 2018 was 58,396,746.63 CNY, indicating a healthy financial position[118]. - The company has not distributed any cash dividends in the past three years, maintaining a 0.00% dividend payout ratio[118]. Revenue and Growth - The company's operating revenue for 2018 was ¥1,439,789,044.56, representing a 22.93% increase compared to ¥1,171,191,341.13 in 2017[18]. - The genetic testing industry accounted for 100% of the total operating revenue, with medical testing services contributing ¥768,198,024.05, which is 53.35% of the total revenue, reflecting an 18.80% increase year-on-year[67]. - The company reported a significant increase in basic research service revenue, which rose by 152.35% to ¥131,438,054.53, accounting for 9.13% of total revenue[67]. - The company is focused on developing high-throughput sequencing technology for non-invasive genetic testing, aiming to provide comprehensive solutions for hereditary disease detection[58]. Research and Development - The company has a strong R&D team, having obtained 13 domestic and international patents, 34 software copyrights, and 83 registered trademarks[47]. - Total R&D investment reached ¥93,380,849.91 in 2018, a 131.92% increase from ¥40,263,807.54 in 2017, representing 6.49% of operating revenue[85]. - R&D expenses increased significantly by 172.00% to ¥91,279,260.87 in 2018 from ¥33,558,469.71 in 2017, attributed to a higher proportion of clinical trial projects[83]. - The company is focused on developing products for early cancer diagnosis and personalized cancer treatment using patented technologies[107]. Market Position and Strategy - The company has established a leading position in the genetic testing market, particularly in the NIPT project, leveraging its first-mover advantage and brand competitiveness[40]. - The company is currently constructing the first phase of its big data center industrial park, which is expected to optimize its production layout and improve its asset structure[44]. - The company aims to establish a comprehensive genetic testing industry chain, covering upstream instrument and reagent development, midstream genetic disease testing services, and downstream consulting and treatment services[107]. - The company plans to leverage its leading position in the gene testing industry to support the tumor business of Fujian and Rui, maximizing resource allocation[105]. Operational Efficiency - The company is implementing new strategies to improve operational efficiency, aiming for a 10% reduction in costs over the next year[123]. - The company has a professional sales team covering the entire country, facilitating the establishment of a large-scale clinical genetic testing network[52]. - The company is focused on reducing related party transactions and ensuring independence in operations and finances[120]. Shareholder and Governance - The company has maintained a stable shareholder structure with no significant changes reported[172]. - The company operates independently from its controlling shareholder in terms of business, personnel, assets, institutions, and finances[200]. - The company has a robust governance structure that aligns with regulatory requirements, ensuring transparency and accountability[198]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management during the reporting period amounted to 3.963 million CNY, with independent directors receiving a total of 240,000 CNY[191]. Risks and Compliance - The company faces risks related to technological innovation delays, increased market competition, and potential fluctuations in product quality[111]. - The management emphasized the importance of compliance and risk management in their future strategies to mitigate potential financial losses[126]. - The company is focused on ensuring compliance with regulations regarding major asset restructuring and abnormal trading activities[122].